drugset / Trial / NCT06563063

Finding ED90 of Flumazenil for Selective Improvement of Respiratory Distress by Remimazolam

NCT06563063

Completed 60 enrolled Yonsei University
NaSequentialOpen-labelSupportive care

Summary

Patients undergoing endoscopic submucosal dissection with monitored anesthesia care (MAC) using remimazolam may develop respiratory distress during the procedure. In these cases, substandard doses of flumazenil have been found to improve respiratory distress without completely reversing sedation, a novel and previously unknown phenomenon. This study aimed to explore the ED90 of flumazenil to selectively improve only respiratory distress during MAC with remimazolam. The dose determination for flumazenil will follow a biased-coin up-and-down design. Starting with an initial dose of 5 mcg, if there is an improvement in respiratory distress, the biased-coin method will be used to administer the same dose to the next patient with a probability of 8/9, and a decreased dose of 5 mcg to the next patient with a probability of 1/9. Any improvement in respiratory distress within 30 seconds of flumazenil administration will be recorded. After the procedure, the patient will be asked if they had any memory recall of the procedure. Centered isotonic regression will be used to obtain the ED90 of flumazenil.

Timeline

Start
2023-08-23
Primary completion
2023-12-01
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Flumazenil Small molecule 5 ug
Subject Flumazenil Small molecule 150 ug

Indications